The grades of seven pharmaceutical stocks are on the rise this week on Portfolio Grader. Each of these stocks is rated an “A” (“strong buy”) or “B” overall (“buy”).

NuPathe Inc. (PATH) is bumping up its rating from a C (“hold”) to a B (“buy”) this week. NuPathe develops pharmaceutical products used for the treatment and management of neurological and psychiatric diseases. In Portfolio Grader’s specific subcategories of Earnings Momentum and Earnings Revisions, PATH also gets A’s. For more information, get Portfolio Grader’s complete analysis of PATH stock.

This is a strong week for GW Pharmaceuticals PLC Sponsored ADR (GWPH). The company’s rating climbs to B from the previous week’s C. For more information, get Portfolio Grader’s complete analysis of GWPH stock.

This week, Watson Pharmaceuticals (WPI) is making solid headway. The company’s rating improves to an A (“strong buy”) from last week’s B (“buy”) rating. Watson develops, manufactures, markets, sells and distributes pharmaceutical products. For more information, get Portfolio Grader’s complete analysis of WPI stock.

This week, Paratek Pharmaceuticals Inc (PRTK) pushes up from a B to an A rating. For more information, get Portfolio Grader’s complete analysis of PRTK stock.

Cardiome Pharma (CRME) earns a B this week, jumping up from last week’s grade of C. Cardiome Pharma focuses on the discovery, development, and commercialization of drugs to treat or prevent cardiovascular and other diseases. Shares of the stock have been trading at an exceptionally rapid pace, up 805.9% from the week prior. For more information, get Portfolio Grader’s complete analysis of CRME stock.

This week, AbbVie, Inc.’s (ABBV) ratings are up from a C last week to a B. AbbVie, a research-based biopharmaceutical company, engages in the discovery, development, manufacture, and sale of pharmaceutical products worldwide. For more information, get Portfolio Grader’s complete analysis of ABBV stock.

Corium International, Inc. (CORI) gets a higher grade this week, advancing from a C last week to a B. Shares of the stock have been changing hands at an unusually rapid pace, up 425.3% from the week prior. For more information, get Portfolio Grader’s complete analysis of CORI stock.

Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.